Clinicians Practice guide

Oral Wegovy: practical clinical pearls

Originally posted Jan 2026 · By Joe Zucchi, PA-C, MPAS

Download JPG ↓Original LinkedIn post ↗

1280 × 719 px · PDF includes the original image and a link to this page.

Joe’s commentary

About this visual

Joe’s January 2026 overview of formulation, administration, and exposure.

Oral Wegovy is here, and I have already seen a lot of confusion online about dosing, formulation, and what actually matters clinically. I made this infographic to put the key pearls in one place.

A few highlights that are easy to overlook:
• Formulation and dosing: the Wegovy tablet strengths (1.5 mg, 4 mg, 9 mg, 25 mg) line up with the newer oral semaglutide platform that looks more like Rybelsus R2 (1.5, 4, 9 mg) than the older Rybelsus R1 (3, 7, 14 mg). That is why comparing “1.5 mg vs 3 mg” can be misleading. The R1 formulation for Rybelsus had 0.4-1% bioavailability whereas the R2 formulation has 1-2% bioavailability.

• Administration matters more than people think. Empty stomach, no more than 4 oz of water, then wait at least 30 minutes before food, drink, or other meds. The label even notes higher exposure with 50 mL water vs 240 mL, and higher exposure with longer post dose fasting. Small routine differences can translate into real exposure differences.

• Bioavailability and variability: oral bioavailability is still low (about 1 to 2%) compared to injection (about 89%), and that is why a 25 mg tablet taken daily can end up producing a similar average drug exposure to a 2.4 mg injection taken weekly. Also the oral tablets have a wider patient to patient exposure range. With 25 mg tablets, 90% of patients are roughly in the range of 27 to 186 nmol/L, whereas with 2.4 mg weekly injection, 90% of patients are roughly 51 to 110 nmol/L. So if patients do not follow the administration directions properly, absorption can be inconsistent, and patients may feel like it “is not working.”

• Side effects look familiar. GI effects are common with both. In OASIS-4, nausea was about 47%, vomiting about 31%, constipation about 20%. The injection label shows nausea about 44%, diarrhea about 30%, vomiting about 24%, constipation about 24%. Same theme, slightly different mix.

• Pricing (2026): list price is around $1,349 per package (same as the injection). Public cash pay offers show $149/month for starter strengths (1.5 mg and 4 mg), with the 4 mg offer at $149 until April 15, 2026, then $199/month. The 9 mg and 25 mg “maintenance” offer is shown around $299/month. Commercial savings are advertised as low as $25/month for eligible patients (coupon takes off up to $100/mo).

Also worth noting: both oral and injectable Wegovy cover weight management and CV risk reduction in adults, but the tablet does not have a pediatric indication and does not have a MASH indication.

I will be covering all of this in more detail on an upcoming episode of The Dr. Francavilla Show with Carolynn Francavilla Brown, MD, MFOMA, DABOM, so stay tuned!

Feel free to leave any questions you getting from patients or colleagues about the oral formulation in the comments.

Sources & further reading

Original LinkedIn post and discussion ↗

Additional references appear in the infographic and the original LinkedIn discussion.

Related visuals

Oral Wegovy: practical clinical pearls

Pinch to zoom on touch devices. Open full image ↗